加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01167 加科思-B

已收盘 03-23 16:08:09

6.230

-0.450

-6.74%

最高6.800	最低6.150	成交量410.75万
今开6.500	昨收6.680	日振幅9.73%
总市值48.97亿	流通市值48.97亿	总股本7.86亿
成交额2,579万	换手率0.52%	流通股本7.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01167","market":"HK","secType":"STK","nameCN":"加科思-B","latestPrice":6.23,"timestamp":1774253289004,"preClose":6.68,"halted":0,"volume":4107494,"delay":0,"changeRate":-0.06736526946107774,"floatShares":786000000,"shares":786000000,"eps":-0.21432665036937226,"marketStatus":"已收盘","change":-0.45,"latestTime":"03-23 16:08:09","open":6.5,"high":6.8,"low":6.15,"amount":25792485,"amplitude":0.097305,"askPrice":6.23,"askSize":3000,"bidPrice":6.2,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.21432665036937226,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"listingDate":1608480000000,"exchange":"SEHK","adjPreClose":6.68,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"volumeRatio":1.628253,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01167","defaultTab":"news","newsList":[{"id":"2621774010","title":"加科思-B(01167)3月23日斥资49.98万港元回购8.01万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774010","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621774010?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:14","pubTimestamp":1774260862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年3月23日，该公司斥资49.98万港元回购8.01万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"gpt_icon":0},{"id":"1174070223","title":"加科思-B：3月23日回购8.01万股，耗资约49.98万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174070223","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174070223?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:01","pubTimestamp":1774260111,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司（股票代码：01167）于2026年3月23日公告称，公司当日于香港联交所场内回购普通股80,100股，占已发行股本约0.01019%。每股回购价介乎6.22港元至6.28港元，总金额为499,779港元。\n回购完成后，公司最新的已发行股本数量为786,039,480股，库藏股增至5,715,600股。公司回购授权于2025年6月10日通过，剩余可回购股份数量为78,873,528股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。\n本公告由公司董事王晓洁签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"2620073579","title":"加科思-B(01167)3月20日斥资50.92万港元回购7.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620073579","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620073579?lang=zh_cn&edition=full","pubTime":"2026-03-20 20:29","pubTimestamp":1774009764,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年3月20日，该公司斥资50.92万港元回购7.62万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"1181559439","title":"加科思-B：3月20日回购7.62万股股份，耗资约50.92万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181559439","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181559439?lang=zh_cn&edition=full","pubTime":"2026-03-20 20:25","pubTimestamp":1774009557,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年3月20日发布公告，披露公司在香港联交所场内回购普通股，相关事项已于当日完成。本次回购股份数量共计76,200股，占公司现有已发行股本约0.00969%。每股价格介乎6.66港元至6.70港元，总耗资约50.92万港元。回购完成后，公司已发行股本合计791,755,080股，其中786,119,580股为流通股份，5,635,500股为库藏股。截至目前，公司已根据该项授权累计回购2,615,700股。公司进一步确认，本次行动已遵守香港联交所上市规则及相关法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"1143185548","title":"加科思-B（01167）回购15万股股份，总额约101.3万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143185548","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143185548?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:06","pubTimestamp":1773921969,"startTime":"0","endTime":"0","summary":"加科思-B于2026年3月19日发布翌日披露报表，宣布于当日回购股份并更新已发行股本情况。根据公告数据，公司当日回购15万股普通股，占当日前已发行股份约0.01908%，回购价格区间介乎每股6.72港元至6.78港元，合计支付约1,013,031港元。截至目前，公司已在交易所累计回购2,539,500股，占授权时已发行股本的0.32197%。公告同时确认上述股份回购行为符合香港联交所《上市规则》及相关法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"1127136226","title":"加科思-B（01167）回购14.4万股股份，总额约99.8万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127136226","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127136226?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:51","pubTimestamp":1773838315,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司（股票代码：01167）于2026年3月18日发布翌日披露报表，公告显示公司当日通过香港联交所场内回购144,000股股份，占回购前已发行股份总数约0.0183%。回购价介乎每股港币6.89元至7.01元，合计支付总额约港币998,043元。\n本次回购后，公司已发行股份（不包括库藏股）总数为786,345,780股，库藏股数为5,409,300股。根据公告，公司于2025年6月10日通过了股份回购授权，可回购股份总数为78,873,528股，而截至目前已在交易所累计回购2,389,500股。公司确认已遵守香港联交所相关上市规则及法例。本次公告由公司董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"2620256365","title":"加科思-B(01167)3月18日斥资99.8万港元回购14.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256365","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620256365?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:51","pubTimestamp":1773838265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年3月18日斥资99.8万港元回购14.4万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"gpt_icon":0},{"id":"1176267587","title":"加科思-B（01167）回购144,000股股份，涉资约100.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176267587","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176267587?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:56","pubTimestamp":1773741372,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年3月17日公告更新翌日披露报表，显示该公司当日回购144,000股普通股，占回购前已发行股份约0.0183%。每股购回价介乎每股6.92港元至7.02港元，合共付出价格1,004,886港元。回购完成后，已发行股份数量降至786,489,780股，库藏股增至5,265,300股，总已发行股本维持在791,755,080股。公司此前于2025年6月10日获得购回授权，可回购最多78,873,528股，截至目前已累计回购2,245,500股，占授权总数约0.2847%。公司在公告中确认，本次回购已遵守香港联交所证券上市规则等相关法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"2620449806","title":"招银国际：料中国医疗行业基本面加速向好 推荐买信达生物(01801)三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449806?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:07","pubTimestamp":1773731228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨0.6%，跑赢MSCI中国指数3.5%。医药行业近期明显回调，特别是创新药板块回调幅度较大。同时，AI制药技术突破与中国创新药踏出海外BD的爆发形成双重共振，该行预计行业基本面加速向好。该行表示，推荐买入信达生物、三生制药、加科思、固生堂 、药明合联，目标价分别110.62港元、37.43港元、10.34港元、44.95港元及88港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d0f3c5bccb622a532fbc5668691928ff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","SG9999014674.SGD","LU1969619763.USD","LU2488822045.USD","159891","02268","LU2097828631.EUR","LU2097828805.USD","01167","LU0455707207.USD","LU2242644610.SGD","LU2097828557.USD","BK1161","01801","LU0502904849.HKD","01530","LU2328871848.SGD","HK0000165453.HKD","BK1574","BK1141","LU2097828714.EUR","BK1583","BK1589","02273","BK1593","LU2097828474.EUR"],"gpt_icon":0},{"id":"1141498184","title":"加科思-B（01167）回购3.9万股股份，耗资约27.4029万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141498184","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141498184?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:20","pubTimestamp":1773660047,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年3月16日公告，基于此前购回授权进行股份购回。公司当日于香港联交所回购39,000股普通股，占该日公司现有已发行股份数目的约0.005%，每股最高回购价为7.04港元、最低回购价为7港元，合计耗资274,029港元。回购完成后，公司已发行股份总数降至786,633,780股，库存股份数目上升至5,121,300股。公司购回授权于2025年6月10日获得批准，授权范围内可购回的股份总数为78,873,528股，截至目前已有2,101,500股在交易所或其他证券交易所完成回购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"2619457377","title":"加科思-B(01167)3月16日斥资27.4万港元回购3.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619457377?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:12","pubTimestamp":1773659570,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年3月16日，该公司斥资27.4万港元回购3.9万股股份，每股回购价7-7.04港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"gpt_icon":0},{"id":"2618180581","title":"每日卖空追踪 | 加科思-B 03月12日卖空量成交11.46万股，卖空比例为2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618180581?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304219,"startTime":"0","endTime":"0","summary":"加科思-B北京时间03月12日，跌2.26%，卖空量成交11.46万股，较上一交易日减少82.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163226a6ba4fc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163226a6ba4fc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","BK1574","BK1161"],"gpt_icon":0},{"id":"2618390270","title":"【券商聚焦】招银国际维持加科思(01167)“买入”评级 Pan-KRAS早期临床数据显示其同类首创重磅潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2618390270","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618390270?lang=zh_cn&edition=full","pubTime":"2026-03-12 13:27","pubTimestamp":1773293273,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，加科思-B(01167)的JAB-23E73（pan-KRAS）展现出了高度差异化的安全性特征和令人鼓舞的早期疗效。该机构认为，由于其与RVMD的RMC-6236等竞品相比具有更优的安全性，加上令人鼓舞的早期疗效信号，JAB-23E73具备成为重磅药物的潜力。该机构预计JAB-23E73经风险调整后的全球峰值销售额将达到21亿美元。此外，公司拥有丰富的在手现金。该机构维持对加科思的“买入”评级，目标价为10.34港元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0},{"id":"2618573180","title":"加科思-B盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618573180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618573180?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:47","pubTimestamp":1773283622,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘10时47分，加科思-B股票出现异动，股价大幅跳水5.08%。截至发稿，该股报6.730港元/股，成交量214.23万股，换手率0.27%，振幅6.21%。加科思-B股票所在的生物技术行业中，整体跌幅为1.56%。其相关个股中，旺山旺水-B、三叶草生物-B、思路迪医药股份涨幅较大，振幅较大的相关个股有中慧生物-B、百奥赛图-B、派格生物医药-B，振幅分别为13.80%、7.08%、6.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210470297aeab1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210470297aeab1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2618996353","title":"港股异动 | 加科思-B(01167)绩后涨超6% 2025年研发管线多点突破 与阿斯利康共同开发JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2618996353","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618996353?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:35","pubTimestamp":1773192931,"startTime":"0","endTime":"0","summary":"截至2025年12月31日，公司拥有380项在全球提交的有效专利或专利申请，其中146项专利已在全球主要市场获颁发或允许。年内，公司与AstraZeneca AB已订立许可与合作协议，共同开发及商业化泛KRAS抑制剂JAB-23E73。根据该许可及合作协议并受其条款及条件所限，北京加科思有权向阿斯利康收取1亿美元的预付款项，并有资格在达成特定开发、监管及商业里程碑时收取额外里程碑付款，总潜在代价最高可达19.15亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00B3T34201.USD","BK4568","01167","BK1574","VXUS","LU2462157665.USD","BK4007","AZN","LU0889565916.HKD","BK4585","LU2236285917.USD","LU0320765992.SGD","LU1829250122.USD","LU2456880835.USD","LU2417539215.USD","LU0109394709.USD","LU0058720904.USD","BK1161","LU0289739699.SGD"],"gpt_icon":0},{"id":"2618995755","title":"Pan-KRAS赛道的新变量：JAB-23E73的胰腺癌ORR 38.5%背后的估值差","url":"https://stock-news.laohu8.com/highlight/detail?id=2618995755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618995755?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192006,"startTime":"0","endTime":"0","summary":"Pan-KRAS赛道最近披露了一组很值得细看的数据。加科思公布了JAB-23E73在胰腺癌患者中的一期研究结果。目前披露的JAB-23E73安全性数据来自42例患者。RMC-6236的血液及肝肾毒性三级治疗相关不良事件为4%-7%，综合来看JAB-23E73安全性更优。JAB-23E73在160mg以上治疗组中，在可评估的13例KRAS突变胰腺癌患者中，有2例是二线治疗，剩下11例都是三线或三线以上的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01167","ORR"],"gpt_icon":0},{"id":"2618954554","title":"加科思-B(01167)2025年研发管线多点突破 国际化布局提速 净亏损同比收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954554","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618954554?lang=zh_cn&edition=full","pubTime":"2026-03-10 23:10","pubTimestamp":1773155438,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B 公布2025年业绩，收入约5350万元，研发开支同比减少42.9%至1.886亿元，行政开支同比减少20.2%至3440万元，净亏损同比收窄6.25%至约1.46亿元。根据该许可及合作协议并受其条款及条件所限，北京加科思有权向阿斯利康收取1亿美元的预付款项，并有资格在达成特定开发、监管及商业里程碑时收取额外里程碑付款，总潜在代价最高可达19.15亿美元。此外，若许可产品成功商业化，北京加科思将有权按许可产品净销售额收取分层特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"gpt_icon":0},{"id":"2618596899","title":"每日卖空追踪 | 加科思-B 03月10日卖空量成交8.52万股，卖空比例为1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618596899","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618596899?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131419,"startTime":"0","endTime":"0","summary":"加科思-B北京时间03月10日，涨9.79%，卖空量成交8.52万股，较上一交易日减少67.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163211a45df667&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163211a45df667&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2618595709","title":"加科思-B盘中异动 股价大涨5.06%报6.440港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618595709","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618595709?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:46","pubTimestamp":1773107173,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时46分，加科思-B股票出现异动，股价大幅上涨5.06%。截至发稿，该股报6.440港元/股，成交量8.67万股，换手率0.01%，振幅4.08%。资金方面，该股资金流入40.6404万港元，流出8.8722万港元。加科思-B股票所在的生物技术行业中，整体涨幅为2.73%。其相关个股中，百奥赛图-B、科济药业-B、康方生物涨幅较大，振幅较大的相关个股有轩竹生物-B、科济药业-B、百奥赛图-B，振幅分别为13.65%、13.43%、11.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031009461397ab7840&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031009461397ab7840&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"1119596590","title":"加科思药业（01167）更新2月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1119596590","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119596590?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:43","pubTimestamp":1772440980,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司（股票代码：01167）于2026年3月2日发布截至2026年2月28日的股份变动月报表。公司已发行普通股数为786,672,780股，另持有5,082,300股库存股份，总股本为791,755,080股，与上月保持一致。\n公司法定注册股本为1,000,000,000股，每股面值USD 0.0001，注册股本总额USD 100,000。截至报告期末，公司无新增股份发行、股份购回或注销活动，股本结构保持稳定。公司同时确认满足香港联交所对公众持股量的相关要求。\n上述公告由董事王晓洁签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jacobiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0443},{"period":"1month","weight":0.0951},{"period":"3month","weight":-0.2627},{"period":"6month","weight":-0.3692},{"period":"1year","weight":0.994},{"period":"ytd","weight":0.0487}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0478},{"period":"1year","weight":0.0437},{"period":"ytd","weight":-0.0138}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"加科思药业集团有限公司是一家主要从事临床阶段新药研发的投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。该公司主要药物开发项目包括JAB-21822及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.0037},{"month":2,"riseRate":0.5,"avgChangeRate":0.158834},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.01089},{"month":4,"riseRate":0.6,"avgChangeRate":0.038742},{"month":5,"riseRate":0.4,"avgChangeRate":0.066021},{"month":6,"riseRate":0,"avgChangeRate":-0.081428},{"month":7,"riseRate":0.4,"avgChangeRate":0.073857},{"month":8,"riseRate":0.2,"avgChangeRate":0.005746},{"month":9,"riseRate":0.6,"avgChangeRate":-0.002238},{"month":10,"riseRate":0.2,"avgChangeRate":-0.065405},{"month":11,"riseRate":0.4,"avgChangeRate":0.020921},{"month":12,"riseRate":0.2,"avgChangeRate":-0.06824}],"exchange":"SEHK","name":"加科思-B","nameEN":"JACOBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"加科思-B,01167,加科思-B股票,加科思-B股票老虎,加科思-B股票老虎国际,加科思-B行情,加科思-B股票行情,加科思-B股价,加科思-B股市,加科思-B股票价格,加科思-B股票交易,加科思-B股票购买,加科思-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}